指南与共识甲状腺与浅表US

初始良性甲状腺结节的恶性风险:多种甲状腺影像报告与数据系统指南的验证

Malignancy risk of initially benign thyroid nodules: validation with various Thyroid Imaging Reporting and Data System guidelines.
指南 / 共识 · Eur Radiol · 2018-06-19

本回顾性研究纳入6493例连续患者共6762个甲状腺结节,其中2747个初始活检诊断为良性并随访28.2±9.1个月,总体恶性率为8.3%(229/2747)。当初始活检良性结节按K-TIRADS、ATA指南评为「低度可疑」、按法国TIRADS评为「很可能良性」或网络版TIRADS评分≤3时,恶性概率≤3.0%。

要点

  • 初始活检良性结节总体恶性率8.3%(229/2747),随访28.2±9.1个月。
  • 按K-TIRADS或ATA评为「低度可疑」、法国TIRADS评为「很可能良性」或网络版TIRADS评分≤3时,恶性概率≤3.0%。
  • 初始活检良性且上述低风险分层结节可影像随访代替二次活检,影像-病理不符者仍需重复活检。

核心结论

  • 初始活检证实良性且按多种TIRADS指南分层为低度可疑超声模式、低恶性概率的结节,可进行影像 surveillance 而非二次活检。

研究设计与样本

  • 回顾性研究,2013年1月至2013年12月连续6493例患者共6762个甲状腺结节接受活检,分析其中2747个初始活检诊断良性且有随访的结节(532名女性,2111名男性;229个恶性,2518个良性),随访28.2±9.1个月(范围12-41个月),以初始活检加≥1年随访作为良性诊断金标准。

诊断标准与关键数值

  • 总体计算甲状腺恶性率为8.3%(229/2747);初始活检良性结节按韩国TIRADS评为「低度可疑」、按ATA指南评为「低度可疑」、按法国TIRADS评为「很可能良性」以及网络版TIRADS评分≤3时,恶性概率≤3.0%。

临床应用与阅片要点

  • 初始活检证实的良性结节若超声表现为「低度可疑」模式且按多种TIRADS指南分层为低恶性概率,可进行影像 surveillance 而非二次活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Some authors have found little or no diagnostic benefit from repeated biopsy of benign thyroid nodules. However, to our knowledge, integration of Thyroid Imaging Reporting and Data System (TIRADS) guidelines with one biopsy for sufficient benign thyroid nodule diagnosis has not been previously described. We investigated malignancy rate and probability by using various malignancy stratification systems in initially biopsy-proven benign nodules and sought to determine their clinical relevance in management of benign thyroid nodules.

METHODS: This retrospective study collected 6762 thyroid nodules from 6493 consecutive patients who underwent biopsy between January 2013 and December 2013. The initial biopsy with ≥1 year of follow-up was used as the gold standard for benign diagnosis. For our study purpose, we analyzed 2747 (57.0%, 2747 of 4822, 532 women, 2111 men; 229 malignant and 2518 benign) thyroid nodules diagnosed by initial biopsy with 28.2 ± 9.1 (range, 12-41) months of follow-up. We calculated the malignancy probability of thyroid nodules by using various malignancy risk stratification systems.

RESULTS: The overall calculated thyroid malignancy rate was 8.3% (229 of 2747). Initially biopsy-proven benign nodules exhibited a ≤3.0% malignancy probability when assessed as "low suspicion" by Korean-TIRADS (K-TIRADS), "low suspicion" by the ATA guideline, and "very probably benign" by the French TIRADS guideline and gave a score of ≤3 by the web-based TIRADS.

CONCLUSION: When initially biopsy-proven benign nodules exhibit a "low suspicion" US pattern and low malignancy probability, as stratified by various TIRADS guidelines, imaging surveillance instead of second biopsy is warranted.

KEY POINTS: • One biopsy is sufficient for initially biopsy-proven benign nodules. • Repetitive biopsy is necessary for imaging-pathology mismatched nodules. • Scoring risk stratification permits personalized management.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ha SM, Baek JH, Choi YJ, et al. Malignancy risk of initially benign thyroid nodules: validation with various Thyroid Imaging Reporting and Data System guidelines. Eur Radiol. 2018. PMID: 29922926. doi:10.1007/s00330-018-5566-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。